These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21482692)

  • 1. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
    Parsels LA; Qian Y; Tanska DM; Gross M; Zhao L; Hassan MC; Arumugarajah S; Parsels JD; Hylander-Gans L; Simeone DM; Morosini D; Brown JL; Zabludoff SD; Maybaum J; Lawrence TS; Morgan MA
    Clin Cancer Res; 2011 Jun; 17(11):3706-15. PubMed ID: 21482692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
    Morgan MA; Parsels LA; Zhao L; Parsels JD; Davis MA; Hassan MC; Arumugarajah S; Hylander-Gans L; Morosini D; Simeone DM; Canman CE; Normolle DP; Zabludoff SD; Maybaum J; Lawrence TS
    Cancer Res; 2010 Jun; 70(12):4972-81. PubMed ID: 20501833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.
    Venkatesha VA; Parsels LA; Parsels JD; Zhao L; Zabludoff SD; Simeone DM; Maybaum J; Lawrence TS; Morgan MA
    Neoplasia; 2012 Jun; 14(6):519-25. PubMed ID: 22787433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
    Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
    J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.
    Parsels LA; Tanska DM; Parsels JD; Zabludoff SD; Cuneo KC; Lawrence TS; Maybaum J; Morgan MA
    Cell Cycle; 2016; 15(5):730-9. PubMed ID: 26890478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
    McNeely S; Conti C; Sheikh T; Patel H; Zabludoff S; Pommier Y; Schwartz G; Tse A
    Cell Cycle; 2010 Mar; 9(5):995-1004. PubMed ID: 20160494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
    Bryant C; Rawlinson R; Massey AJ
    BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776.
    Engelke CG; Parsels LA; Qian Y; Zhang Q; Karnak D; Robertson JR; Tanska DM; Wei D; Davis MA; Parsels JD; Zhao L; Greenson JK; Lawrence TS; Maybaum J; Morgan MA
    Clin Cancer Res; 2013 Aug; 19(16):4412-21. PubMed ID: 23804422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
    Zhou J; Chen Z; Malysa A; Li X; Oliveira P; Zhang Y; Bepler G
    PLoS One; 2013; 8(3):e58091. PubMed ID: 23483975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
    Grabauskiene S; Bergeron EJ; Chen G; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
    J Surg Res; 2014 Mar; 187(1):6-13. PubMed ID: 24418519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
    Zabludoff SD; Deng C; Grondine MR; Sheehy AM; Ashwell S; Caleb BL; Green S; Haye HR; Horn CL; Janetka JW; Liu D; Mouchet E; Ready S; Rosenthal JL; Queva C; Schwartz GK; Taylor KJ; Tse AN; Walker GE; White AM
    Mol Cancer Ther; 2008 Sep; 7(9):2955-66. PubMed ID: 18790776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
    Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
    Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.
    Xu H; Cheung IY; Wei XX; Tran H; Gao X; Cheung NK
    Int J Cancer; 2011 Oct; 129(8):1953-62. PubMed ID: 21154747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
    Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
    Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
    Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
    Oza V; Ashwell S; Almeida L; Brassil P; Breed J; Deng C; Gero T; Grondine M; Horn C; Ioannidis S; Liu D; Lyne P; Newcombe N; Pass M; Read J; Ready S; Rowsell S; Su M; Toader D; Vasbinder M; Yu D; Yu Y; Xue Y; Zabludoff S; Janetka J
    J Med Chem; 2012 Jun; 55(11):5130-42. PubMed ID: 22551018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
    Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
    Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
    Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo.
    Ma Z; Yao G; Zhou B; Fan Y; Gao S; Feng X
    Mol Med Rep; 2012 Oct; 6(4):897-903. PubMed ID: 22825736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.
    Rawlinson R; Massey AJ
    BMC Cancer; 2014 Jul; 14():483. PubMed ID: 24996846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.